An objective of the present invention is to provide a pharmaceutical agent for the prevention or treatment of the acute renal failure which is caused by the persistence or aggravation of systemic inflammatory response syndrome due to trauma, burns, pancreatitis, sepsis, or infection； disseminated intravascular coagulation syndrome； multiple organ failure； peripheral arterial occlusive disease； arteriosclerosis obliterans； and Crush syndrome； or posttransplantation complications. The present invention is a preventive or therapeutic agent for acute renal failure which includes the hydantoin derivative represented by the following general formula as an active ingredient. Of the compounds, (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide is particularly preferable. wherein X represents a halogen atom or a hydrogen atom, R1 and R2 independently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R 1 and R 2 , together with a nitrogen atom bound thereto, or optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.
